BIOCRYST PHARMACEUTICALS INC Share-based Payment Arrangement, Expense in USD from 2012 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Biocryst Pharmaceuticals Inc quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from 2012 to Q3 2025.
  • Biocryst Pharmaceuticals Inc Share-based Payment Arrangement, Expense for the quarter ending September 30, 2025 was $18.6M, a 7.84% increase year-over-year.
  • Biocryst Pharmaceuticals Inc Share-based Payment Arrangement, Expense for the twelve months ending September 30, 2025 was $82.6M, a 36.4% increase year-over-year.
  • Biocryst Pharmaceuticals Inc annual Share-based Payment Arrangement, Expense for 2024 was $65.4M, a 17.6% increase from 2023.
  • Biocryst Pharmaceuticals Inc annual Share-based Payment Arrangement, Expense for 2023 was $55.6M, a 24.4% increase from 2022.
  • Biocryst Pharmaceuticals Inc annual Share-based Payment Arrangement, Expense for 2022 was $44.7M, a 29% increase from 2021.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Growth (%)

BIOCRYST PHARMACEUTICALS INC Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 $82.6M $18.6M +$1.35M +7.84% Jul 1, 2025 Sep 30, 2025 10-Q 2025-11-04
Q2 2025 $81.3M $21.3M +$8.13M +61.7% Apr 1, 2025 Jun 30, 2025 10-Q 2025-08-05
Q1 2025 $73.1M $21.4M +$7.72M +56.5% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-06
Q4 2024 $65.4M $21.3M +$4.85M +29.4% Oct 1, 2024 Dec 31, 2024 10-K 2025-02-25
Q3 2024 $60.6M $17.2M +$4.97M +40.5% Jul 1, 2024 Sep 30, 2024 10-Q 2025-11-04
Q2 2024 $55.6M $13.2M +$332K +2.59% Apr 1, 2024 Jun 30, 2024 10-Q 2025-08-05
Q1 2024 $55.3M $13.7M -$355K -2.53% Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-06
Q4 2023 $55.6M $16.5M Oct 1, 2023 Dec 31, 2023 10-K 2025-02-25
Q3 2023 $12.3M Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-05
Q2 2023 $12.8M Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-06
Q1 2023 $14M +$4.41M +45.9% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-07
Q1 2022 $9.6M +$4.12M +75.2% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-08
Q1 2021 $5.48M +$2.73M +98.9% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-09
Q1 2020 $2.75M -$563K -17% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-07
Q1 2019 $3.32M +$414K +14.3% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-11
Q1 2018 $2.9M +$441K +17.9% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-09
Q1 2017 $2.46M +$2.46M Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-09
Q1 2016 $2.65K* -$2.26M Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-08
Q1 2015 $2.26M +$649K +40.3% Jan 1, 2015 Mar 31, 2015 10-Q 2016-05-09
Q1 2014 $1.61M Jan 1, 2014 Mar 31, 2014 10-Q 2015-05-08

BIOCRYST PHARMACEUTICALS INC Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $65.4M +$9.8M +17.6% Jan 1, 2024 Dec 31, 2024 10-K 2025-02-25
2023 $55.6M +$10.9M +24.4% Jan 1, 2023 Dec 31, 2023 10-K 2025-02-25
2022 $44.7M +$10.1M +29% Jan 1, 2022 Dec 31, 2022 10-K 2025-02-25
2021 $34.6M +$19.8M +134% Jan 1, 2021 Dec 31, 2021 10-K 2024-02-27
2020 $14.8M -$2.93M -16.5% Jan 1, 2020 Dec 31, 2020 10-K 2023-02-27
2019 $17.7M +$8.32M +88.6% Jan 1, 2019 Dec 31, 2019 10-K 2022-02-28
2018 $9.4M -$3.23M -25.6% Jan 1, 2018 Dec 31, 2018 10-K 2021-03-01
2017 $12.6M +$4.13M +48.7% Jan 1, 2017 Dec 31, 2017 10-K 2020-03-13
2016 $8.49M -$1.22M -12.6% Jan 1, 2016 Dec 31, 2016 10-K 2019-03-14
2015 $9.71M -$472K -4.64% Jan 1, 2015 Dec 31, 2015 10-K 2018-03-12
2014 $10.2M +$5.81M +133% Jan 1, 2014 Dec 31, 2014 10-K 2017-02-27
2013 $4.37M +$201K +4.82% Jan 1, 2013 Dec 31, 2013 10-K 2016-02-26
2012 $4.17M Jan 1, 2012 Dec 31, 2012 10-K 2015-03-02
* An asterisk sign (*) next to the value indicates that the value is likely invalid.